Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Giada Benasi^a Jenny Guidi^a Emanuela Offidani^b Richard Balon^c
Karl Rickels^d Giovanni A. Fava^{a, e}

^aDepartment of Psychology, University of Bologna, Bologna, Italy; ^bPennsylvania State University, Schuylkill Haven, PA, USA; ^cDepartments of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University School of Medicine, Detroit, MI, USA; ^dDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; ^eDepartment of Psychiatry, State University of New York at Buffalo, Buffalo, NY, USA

Keywords

Benzodiazepines · Depression · Antidepressant drugs · Systematic review · Meta-analysis · Placebo · Randomized controlled trials · Anxiety

Abstract

Background: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. **Methods:** Keyword searches were conducted for identifying RCT comparing BZD and AD, and/or placebo in the treatment of depression, using electronic databases from their inception up to April 2017. We selected reports of RCT in which BZD were compared to AD and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression. When feasible, data were subjected to meta-analysis. **Results:** A total of 38 studies met the criteria for inclusion and were then included in the systematic review. Only 1 study concerned a newer AD, fluvoxamine. For the meta-analysis, we submitted data on response rate from 22 RCT, considering BZD versus

placebo (8 comparisons) and BZD versus tricyclic antidepressants (TCA) (20 comparisons). There was a lack of significant differences as to response rate between BZD and placebo, as well as between BZD and TCA. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were significantly more effective than placebo and as effective as TCA. **Conclusions:** BZD are a therapeutic option in anxious depression and there are no indications that AD are preferable. There is a pressing need for RCT of adequate methodological quality and follow-up comparing BZD to second-generation AD and placebo in anxious depression.

© 2018 S. Karger AG, Basel

Introduction

Benzodiazepines (BZD) are often used in the treatment of depression in addition to antidepressant drugs (AD) in order to address any initial symptoms of anxiety [1–5]. However, data regarding the use of BZD as a monotherapy and their specific antidepressant action are lacking.

The reviews available in the literature are older than 20 years, are not systematic, and lack important information about the inclusion criteria of the reported studies. In 1978, Schatzberg [6] analyzed 20 double-blind controlled trials in which BZD were compared to AD, or to AD and placebo for the treatment of depressive disorders. They concluded that, even though BZD may elevate mood, they exert limited effects on the core symptoms of depression. Subsequent published reviews on the comparisons between BZD and AD, and/or placebo in the treatment of depression [7–9] did not yield clear indications.

The aim of this paper was to provide a systematic review of the use of BZD in depressive disorders, including only studies involving a monotherapy compared with AD and/or AD. Particular attention was paid to anxious depression, since it is a highly prevalent condition [10] for which AD are likely to yield limited responses [11].

Methods

Data Sources

PRISMA guidelines [12] were used to conduct a systematic review of the literature to identify randomized controlled trials (RCT) comparing BZD and AD, and/or placebo for the treatment of depression and anxious depression. Keywords were: “depression,” “benzodiazepine,” and “antidepressant.” From each of these words, a more extensive list of terms was obtained, including: “alprazolam,” “adinazolam,” “bromazepam,” “clonazepam,” “chlordiazepoxide,” “diazepam,” “lorazepam,” “major depressive disorder,” “dysthymic disorder,” “minor depression,” “neurotic depression,” “reactive depression,” “endogenous depression,” “melancholic depression,” “catatonic depression,” “atypical depression,” “seasonal depression,” “postpartum depression,” “psychotic depression,” “anxious depression,” “mixed anxiety depression,” “TCA,” “tricyclic antidepressant,” “amitriptyline,” “clomipramine,” “desipramine,” “dosulepin,” “doxepin,” “imipramine,” “nortriptyline,” “SSRI,” “serotonin reuptake inhibitor,” “citalopram,” “escitalopram,” “fluoxetine,” “fluvoxamine,” “paroxetine,” and “sertraline.” Only published trials in the English language were considered for inclusion. Electronic databases included PsycINFO, PsycARTICLES, CINAHL, the Cochrane Library, MEDLINE, Web of Science, KCI-Korean Journal Database and SciELO citation index, from the inception of each database up to April 2017. Reference lists from relevant studies and reviews were examined for further clinical trials not yet identified. Authors of significant articles and other experts in the field were contacted.

Study Selection

The search and the rating of target responses were carried out independently by 2 investigators (G.B. and E.O.); disagreements were resolved by consensus by these primary raters and a senior investigator (G.A.F.). We selected English reports of RCTs in which BZD were compared to antidepressants (AD) and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression.

We excluded (a) nonrandomized controlled trials, (b) studies conducted with nonclinical samples, (c) those including patients <18 years of age, (d) symptoms of depression and anxiety occurring in the context of primary diagnoses other than unipolar depressive disorders. We further excluded trials in which (e) BZD were not directly compared with AD or placebo, (f) BZD, AD, or placebo were administered in combination with other treatments, (g) patients were affected by bipolar depression, anxiety disorders, or other conditions were included without a separate analysis of the results, (h) no data about age were reported, and (i) the antidepressant effect of BZD was not assessed.

The primary outcome measure was response rate, according to standardized instruments and the clinician’s global evaluation. Secondary outcome measures were the dropout rate and the occurrence of adverse events during treatment.

Data Extraction

Data were independently extracted by both reviewers with the use of a precoded form. The following data were extracted from studies meeting the criteria for inclusion in the systematic review: study design; demographics (age, gender distribution, and size of the sample); the primary diagnosis and other features (severity, clinical subgroups, and setting); the methods used to define response to treatment and adverse events; the type, duration, and dose of pharmacological treatment; group comparisons and the number of patients randomized to each treatment arm; response rate and dropout rate (and reasons); the frequency and severity of adverse events; and details about compliance, length of follow-up, and treatment discontinuation.

The methodological quality of the included trials was assessed on 2 levels. At the study level, we considered the presence of random allocation of treatments and blinding of outcome assessment; at the outcome level, we considered the presence of intent-to-treat analysis (ITT). Definitions of withdrawal, postwithdrawal, and rebound symptomatology were based on the criteria developed by Chouinard and Chouinard [13].

Data Synthesis

When feasible, data were subjected to a meta-analysis. The primary outcome of the meta-analysis was treatment efficacy, expressed as response rate. Therefore, the risk ratio (RR) of response and its standard error (SE) were calculated from each eligible study. Examination of the pooled results was performed based on the random-effects model to increase the generalizability of findings, since this model is more conservative than the fixed-effects model. An α level of 0.05 was used for hypothesis tests.

In addition to point estimates and confidence intervals, the Q statistic was performed to assess heterogeneity between study results. With this statistic, the null hypothesis is tested that effect sizes from each of the studies were similar enough for a common population effect size to be calculated [14]. However, the Q statistic only informs about the presence versus the absence of heterogeneity; it does not report on the extent of such heterogeneity. The I^2 statistic, which is an indicator of heterogeneity in percentages, was also calculated. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity: 25% = low, 50% = moderate, and 75% = high heterogeneity [15].

The likelihood of significant publication bias was assessed with the Begg funnel plot [16], and testing for asymmetry using the Egger test statistic [17]. Sensitivity analyses were implement-

ed in order to estimate the influence of each study, by deleting each in turn from the analysis and noting the degree to which the size and significance of the treatment effect changed. Meta-regression was performed to investigate how certain characteristics (i.e., treatment duration, the presence of comorbid anxiety symptoms and ITT) acted to influence the treatment effects. Finally, clinical heterogeneity between studies was explored performing subgroup analyses based on the presence of comorbid anxiety symptoms (i.e., anxious vs. nonanxious depression). All analyses were conducted by J.G. using the user-written packages for meta-analysis available in Stata v10.1 (Stata Corp., College Station, TX, USA).

Results

Characteristics of the Included Studies

The initial search identified 10,355 reports (online suppl. Fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000486696). After adjusting for duplicates, the abstracts and titles of 2,190 reports were screened for a first evaluation. Of these, 2,120 did not meet the inclusion criteria and were excluded. Main reasons for exclusion were: language (i.e., other than English), sample characteristics (i.e., animals, children, adolescents, or a nonclinical population), type of document (i.e., comment, case report, pilot study, review, meta-analysis), another primary diagnosis (e.g., bipolar disorder, anxiety disorder, psychotic disorder, and substance abuse), and the experimental condition (e.g., a comparison with antipsychotics or a combination with other drugs, ECT, or psychotherapy). The full texts of the remaining 70 studies were then analyzed, with the additional elimination of 32 studies. Eight of these concerned subjects <18 years of age or did not report any information about age, 7 compared BZD with ECT, psychotherapy, drug combinations or nonantidepressant medications, 1 did not evaluate the antidepressant effects of BZD, 3 were renamed copies of the same study and did not satisfy the blinded randomization criterion, 2 reported data on a subsample of subjects that were included in the main study, and 11 included subjects with anxiety or bipolar disorders in the total sample without a separate analysis of results.

Therefore, a total of 38 studies met the criteria for inclusion. Three compared BZD and placebo, 13 compared BZD and tricyclic antidepressants (TCA) and placebo (3 studies involved 2 BZD), and 21 compared BZD and TCA for the treatment of depression with or without comorbid anxiety. Only 1 study concerned newer AD. All these studies will be summarized and critically reviewed.

For the meta-analysis, we submitted data on response rate from 22 RCT involving BZD versus placebo (8 comparisons) and BZD versus TCA (20 comparisons) as separate analyses.

Systematic Review of RCT on the Efficacy of BZD in the Treatment of Depressive Disorder

BZD versus Placebo

Anxious Depression. One study found no significant differences between clordiazepoxide and placebo in mixed anxiety/depression [18] (online suppl. Table 1).

Nonanxious Depression. Two reports showed adinazolam to be associated with a rapid onset of action and significantly greater efficacy than placebo in the treatment of DSM-III major depressive disorder [19, 20] (online suppl. Table 1). Smith and Glaudin [19] reported no medical events after abrupt or tapered discontinuation of adinazolam, and Cohn et al. [20] observed no seizures after gradual tapering of adinazolam.

BZD versus TCA and Placebo

Anxious Depression. Nine reports compared BZD with TCA and placebo in the treatment of mixed anxiety/depressive states [21–23], reactive or neurotic depression [24], major depressive disorder with symptoms of anxiety [25–28], and ICD-9 neurotic depression or affective psychosis [29] (online suppl. Table 1).

Regarding efficacy, in 6 studies, all active treatments were significantly more effective than placebo, with no significant differences between BZD and TCA [21, 24–26, 28, 29]. Only alprazolam, and not amitriptyline, differed significantly from placebo in the study by Imlah [24], and the difference between active treatments and placebo did not reach a significant level in Rickels et al. [25]. In 3 of these studies, BZD showed a faster onset of action than TCA [24, 25, 29]. Results in favor of BZD were found in 1 study [23], in which bromazepam was associated with a faster onset of action and a significantly greater improvement than amitriptyline. Lastly, in 2 of the studies, response to treatment was significantly greater with TCA, with no differences between clordiazepoxide and placebo [22, 27].

Dropout rates were significantly higher among patients treated with placebo, presumably due to ineffectiveness [21, 26] and/or deterioration [23, 24, 27], and in those treated with TCA due to the side effects [21, 23, 26, 27]. No significant differences in attrition rates were observed between BZD and TCA and placebo in 2 studies [22, 25]. Adverse reactions, such as anticholinergic symptoms, agitation, and tachycardia were more frequently reported for TCA [21, 24–28], while BZD generally resulted

in greater drowsiness [27, 28]. However, in Rickels et al. [21, 26], sedation and drowsiness occurred significantly more frequently with all active treatments compared with placebo. In Shammass [23], the proportion of patients experiencing side effects was similar with bromazepam and amitriptyline, and was significantly higher for both medications compared to placebo. No withdrawal reactions or nightmares were observed by Shammass [23] and Laakman et al. [29].

Nonanxious Depression. Four reports compared BZD with TCA and placebo in patients suffering from DSM-III major depressive disorder [30, 31], with melancholic characteristics in 2 cases [32, 33] (online suppl. Table 1).

As for the response to treatment, in 1 of these studies, alprazolam and imipramine were significantly more effective than placebo and produced a comparable effect [30]. In 2 of them, TCA yielded a significantly greater improvement than both BZD and placebo [31, 33]. In the fourth study, both alprazolam and imipramine were significantly more effective than diazepam and placebo [32]. Most of these studies reported a faster action with BZD than with TCA [30–32].

Dropouts due to ineffectiveness were significantly more frequently associated with placebo [30–32] whereas those due to side effects were significantly more prevalent among patients treated with TCA [30, 31], except for 1 study [32]. Two investigations provided follow-up data 1 week after the end of treatment, during which the dosage was decreased to 50% for 3 days and then to zero for 4 more days. Rickels et al. [32] reported a slight worsening only in the alprazolam- and diazepam-treated groups, but no changes with imipramine and placebo. Rickels et al. [31] documented that only adinazolam resulted in a rebound of symptoms.

BZD versus TCA

Anxious Depression. Seven reports directly compared BZD and TCA in patients suffering from mixed anxiety/depressive states [34–37], neurotic depression [38, 39], and DSM-III major depressive disorder with anxiety [40] (online suppl. Table 1).

In 5 studies [35, 37–40], there were no significant differences between BZD and TCA. Results significantly favoring TCA over BZD were found in the remaining 2 studies [34, 36].

As for adverse reactions, a significantly greater number of side effects was reported in patients treated with TCA by Singh et al. [38], whereas a comparable likelihood of reporting side effects was observed with both BZD and TCA in 3 other studies [35, 37, 39].

Nonanxious Depression. Fourteen reports compared BZD and TCA in the treatment of depression [41, 42], major depressive disorder [43–47], and serious forms of endogenous depression [48–53] including 1 with melancholic characteristics [54] (online suppl. Table 1).

Regarding response to treatment, 9 of these studies found an overall improvement, with no significant differences across medication classes [41–43, 45, 46, 49, 51, 52, 54], even in the setting of melancholia [54], in both outpatients and inpatients [49]. Results significantly favoring the use of TCA were found in 4 studies [44, 47, 48, 50]. However, in Rush et al. [50], alprazolam showed a more rapid action than TCA, with a significantly higher percentage of alprazolam-treated patients considered as being in remission after 1 week of treatment. Eriksson et al. [44] found that amitriptyline was significantly superior to alprazolam only in a subgroup of patients suffering from depression with psychomotor retardation, a low level of anxiety, and an absence of precipitating factors, but they found no differences between treatments in the other cases. Finally, in Ansseau et al. [53], amitriptyline was significantly more effective than diazepam; adinazolam showed an intermediate position between amitriptyline and diazepam, with amitriptyline being significantly superior to adinazolam only on the endogenomorphy subscale.

Dropout rates were estimated to be approximately similar for both medication classes in 4 studies [43, 45, 47, 52]. However, in Hubain et al. [52], a significantly greater number of alprazolam-treated patients dropped out of the study (due to ineffectiveness) than amitriptyline-treated patients. The dropout rate was significantly greater with TCA in 2 studies [46, 51]; in Ansseau et al. [53], it was significantly more common with diazepam than with amitriptyline due to ineffectiveness after 2 weeks. Adverse reactions, such as anticholinergic symptoms, were significantly more frequent with TCA in 5 studies [42, 44–46, 53], but no differences were observed between TCA and BZD in 3 other reports [41, 47, 52].

No withdrawal symptoms were observed by Ansseau et al. [53] after tapered discontinuation of all medications, and Goldberg et al. [43] reported only 1 case in which the abrupt discontinuation of alprazolam caused a seizure (withdrawal reactions were not systematically investigated).

BZD versus Newer AD

Laws et al. [55] compared lorazepam to fluvoxamine in the treatment of 112 subjects affected by a mixed state of anxiety and depression (online suppl. Table 1). They

Fig. 1. Efficacy of benzodiazepines versus placebo in the treatment of depressive disorder with or without comorbid anxiety ($n = 8$). RR, risk ratio.

observed no differences between the 2 medications. Compliance and adverse events were similar for both drugs, even though nausea and vomiting were significantly more frequently observed among fluvoxamine-treated patients.

Meta-Analysis on the Efficacy of BZD in the Treatment of Depressive Disorder

Twenty-two reports contributed data for the meta-analysis. Participants were assigned at random to the conditions in all studies, and all were double-blind trials. ITT analyses were performed in 8 reports [19, 20, 23, 28, 30, 31, 42, 53], completers' data only were reported in 12 studies [25, 27, 29, 37, 39, 41, 44, 45, 47, 49, 50, 54], and handling of attrition was not reported in 2 studies [46, 48].

BZD versus Placebo

Eight studies contributed data for the meta-analysis of response rate comparing BZD and placebo in the treatment of depressive disorder with or without comorbid anxiety [19, 20, 25, 27–31]. They reported response rates for a total of 1,302 participants (723 patients in the BZD treatment arm and 579 in the placebo arm). Participants averaged 40.1 (SD 3.0) years of age, and 64.9% (range 45.9–75%) were female.

The data did not show significant differences in the response rate between BZD and placebo (Fig. 1). The

pooled RR for response was 1.878 (95% CI 0.574–6.145; $p = 0.297$) in the random-effects model. Heterogeneity across trials was statistically not significant ($Q = 0.442$; $df = 7$; $p = 1.000$). The I^2 statistic also indicated no significant heterogeneity (0%) among the pooled studies. Visual inspection of the Begg funnel plot and the Egger test ($p = 0.886$) did not suggest the presence of publication bias. A sensitivity analysis was performed to determine the contribution of each study to the overall effect size, and no study appeared to markedly influence the observed RR for response.

Performing meta-regression analysis, we did not find any significant effect of the abovementioned characteristics (i.e., treatment duration, the presence of comorbid of anxiety symptoms, and ITT) on the response rate among the included studies.

Subgroup analyses were also performed, considering anxious depression and nonanxious depression separately. No significant differences were detected between BZD and placebo as to response rate in both anxious (RR = 1.818, 95% CI 0.339–9.758, and $p = 0.486$, based on 4 studies) and nonanxious depression (RR = 1.940, 95% CI 0.364–10.328, and $p = 0.437$, based on 4 studies).

BZD versus TCA

Twenty studies contributed data for the meta-analysis of response rate comparing BZD and TCA in the treatment of depressive disorder with or without comorbid

Fig. 2. Efficacy of benzodiazepines versus tricyclic antidepressants in the treatment of depressive disorder with or without comorbid anxiety ($n = 20$). RR, risk ratio.

anxiety [23, 25, 27–31, 37, 39, 41, 42, 44–50, 53, 54]. They reported response rates for a total of 2,118 participants (1,146 patients in the BZD treatment arm and 972 in the TCA arm). Participants averaged 40.2 (SD 5.05) years of age, and 67.6% (range 43.3–86.4%) were female.

The pooled RR for response was 0.809 (95% CI 0.514–1.273; $p = 0.359$) in the random-effects model, suggesting no significant differences in response to treatment with BZD and TCA (Fig. 2). Heterogeneity across trials was statistically not significant ($Q = 4.772$; $df = 19$; $p = 1.000$). The I^2 statistic also indicated not significant heterogeneity (0%) among the pooled studies. The visual inspection of the Begg funnel plot and the Egger test ($p = 0.379$) did not suggest the presence of publication bias. A sensitivity analysis was performed to determine the contribution of each study to the overall effect size, and no study appeared to markedly influence the observed RR for response.

Performing meta-regression analyses, we did not find any significant effect of the abovementioned characteristics (i.e., treatment duration, the presence of comorbid anxiety symptoms, and ITT) on response rate among the included studies.

Subgroup analyses were performed, considering anxious depression and nonanxious depression separately.

We did not find significant differences in the response rate with BZD and with TCA in the treatment of both anxious (RR = 1.172, 95% CI 0.482–2.848, and $p = 0.727$, based on 7 studies) and nonanxious depression (RR = 0.709, 95% CI 0.418–1.203, and $p = 0.203$, based on 13 studies).

Discussion

Our systematic review included 38 RCT examining the efficacy of BZD in the treatment of depression. None of these studies was conducted after 1990s and most of them compared BZD to TCA and/or placebo, with only 1 involving newer AD. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were found to be significantly more effective than placebo and as effective as TCA. In 11 studies, TCA were better than BZD, while BZD were better than TCA in only 1. In 12 of these studies, BZD were associated with a faster onset of action than TCA [23–25, 29–32, 38, 43, 45, 50, 51]. Dropouts due to ineffectiveness were more frequently observed in the placebo group, while in the TCA group they were more likely to be associated with adverse reactions. Furthermore,

side effects recurred more frequently with TCA, while BZD induced more drowsiness and cognitive impairment.

Only the studies that were deemed to share certain clinical characteristics *a priori* [56] were included in the meta-analysis, the main findings of which were lack of significant differences as to response rate between BZD and placebo as well as between BZD and TCA. Even though most of the studies recruited depressed patients with anxiety symptoms, an attempt was made to analyze clinical subgroups according to the presence of comorbid anxiety (i.e., anxious depression) separately. These subgroup analyses confirmed the previous result of a lack of significant differences in response rate between BZD and placebo and BZD and TCA in both anxious and nonanxious depression.

The interpretation of these findings is hampered by a number of methodological problems: small sample sizes, the presence of a wide variability across studies regarding treatment duration (ranging from 3 to 12 weeks), diagnosis definition (interestingly, it is only in DSM-5 that an “anxious distress” specifier was added to the diagnosis of depressive disorder), inclusion criteria, methods used to evaluate response to treatment, information about severity, adverse reactions or dropouts, and the use of ITT analysis. Furthermore, very little information was available about the long-term antidepressant efficacy of BZD and TCA. Two studies [31, 32] with a follow-up 1 week after the treatment reported a worsening with BZD but not with TCA. Laakman et al. [29] observed a comparable worsening in all the BZD, TCA, and placebo groups after 2, 4, and 6 weeks of follow-up.

The only study comparing BZD and newer AD [55] did not find significant differences in response to treatment between lorazepam and fluvoxamine in the treatment of mixed anxiety/depression, with a better tolerability of BZD. These findings should be considered with caution, since subjects who dropped out during the first 2 weeks of treatment were not included in the efficacy analysis and a placebo control group was lacking. It is indeed difficult to draw firm conclusions about the comparative efficacy of BZD and TCA (or newer AD) when studies do not include a placebo control group.

Finally, our systematic review relied on published findings only. This could explain the paucity of trials on the comparison between BZD and newer AD, since the financial interests in the latter may have led to a selective publication of results about their efficacy [57, 58].

This systematic analysis of the literature, even considering these limitations, has shown BZD to be as effective

as AD, with a faster action and better tolerability, in the short-term treatment of depression, particularly with comorbid anxiety symptoms and regardless of the severity of the major depressive disorder. A secondary analysis [59] of data, obtained by Rickels et al. [21], reported many significant interactions between drug and patient subgroups within a 4-week period, e.g., a lack of significant differences between treatment groups in cases of low levels of anxiety and depression, greater efficacy of clordiazepoxide and amitriptyline than placebo in cases of high levels of anxiety and depression, greater efficacy of amitriptyline than clordiazepoxide and placebo in cases of high levels of depression and low levels of anxiety, and greater efficacy of clordiazepoxide than amitriptyline and placebo in cases of high levels of anxiety and low levels of depression.

These findings have important clinical implications for the treatment of anxious depression. About half of outpatients with major depressive disorder also have clinically meaningful anxiety, measured either by a dimensional approach or with co-occurring anxiety disorder [11, 60]. Such characterization should be differentiated from mixed anxiety-depression [61], which is concerned with subsyndromal symptoms that do not reach the threshold diagnosis of major depressive disorder, generalized anxiety disorder, or any other full-syndrome disorder [60]. Anxious depression tends to display a worse response to AD than other forms of depression [11], and AD are not more effective than placebo in the treatment of minor or subthreshold depression [62, 63]. Nevertheless, AD, especially SSRI and SNRI, are considered to be a primary choice for treating anxious depression [2–4] as well as anxiety disorders, despite the fact that direct comparisons indicate that BZD are more effective and tolerable than AD for the latter [64–66]. Dosages of BZD used in trials concerned with depression were comparable to those employed in the treatment of anxiety [64–66].

The findings of our meta-analysis confirm the low response of anxious depression to psychotropic drug treatment, whether AD or BZD, which failed to display any significant differences when compared to placebo. At the same time, however, there was no evidence to support the superiority of AD over BZD in anxious depression. BZD, however, are portrayed as having a marginal role in the treatment of depression, because of concerns about toxicity, abuse, and dependence. Such risks, usually associated with a prolonged use of BZD, have been widely emphasized in the literature, even though the evidence does not support these concerns [67–69]. The risk of abuse of BZD is actually rather low considering the number of people

who use these compounds [69, 70]. Withdrawal reactions may follow after the discontinuation of both BZD and AD [13, 71, 72]. Furthermore, while BZD have been related to greater sedation, anterograde amnesia, and cognitive or psychomotor impairment [64, 69], long-term treatment with SSRI and SNRI has been linked to serious side effects such as gastrointestinal symptoms, weight gain, and metabolic abnormalities, cardiovascular disturbances, sexual dysfunction, osteoporosis and the risk of fractures, bleeding, and behavioral toxicity [73–75]. Finally, the initiation of treatment with AD may be hampered by symptoms such as jitteriness [76], especially in anxious patients.

BZD may thus be considered in the treatment of anxious depression, with attention to compounds that are less likely to induce dependence, such as clonazepam [69]. The temporary use of BZD may attenuate a patient's

anxious and depressive symptoms, and, if associated with psychotherapeutic management (the application of psychological understanding in the management of the patient, which includes helping them to identify and deal with current life situations, without the use of formal psychotherapy), may improve the overall clinical picture. The results do not provide evidence (in terms of efficacy, side effects, or dependence) to support the clinical stance that AD should be preferred in the range of mild severity. There is a pressing need for RCT of adequate methodological quality and follow-up [77] that compare BZD, second-generation AD, and placebo in the treatment of anxious depression.

Disclosure Statement

No conflicts of interest were reported.

References

- 1 Furukawa TA, Streiner DL, Young LT: Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. *J Affect Disord* 2001;65:173–177.
- 2 American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, ed 3. Arlington, APA, 2010.
- 3 Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry* 2013;14:334–385.
- 4 Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller H-J: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: Maintenance treatment of major depressive disorder – update 2015. *World J Biol Psychiatry* 2015;16:76–95.
- 5 Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM, Katona C, Lewis G, Malizia A, McAllister-Williams RH, Ramchandani P, Scott J, Taylor D, Uher R: A revision of the 2008 British Association for Psychopharmacology guidelines. *J Psychopharmacol* 2015;29:459–525.
- 6 Schatzberg AF: Benzodiazepines in depressive disorders. *Arch Gen Psychiatry* 1978;35:1359–1365.
- 7 Johnson DA: The use of benzodiazepines in depression. *Br J Clin Pharmacol* 1985;19(suppl 1):31S–35S.
- 8 Birkenhäger TK, Moleman P, Nolen WA: Benzodiazepines for depression? A review of the literature. *Int Clin Psychopharmacol* 1995;10:181–195.
- 9 Petty F, Trivedi MH, Fulton M, Rush AJ: Benzodiazepines as antidepressants: does GABA play a role in depression? *Biol Psychiatry* 1995;38:578–591.
- 10 Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, Bunting B, Demeytenaere K, Florescu S, de Girolamo G, Gureje O, He Y, Hu C, Huang Y, Karam E, Kovess-Masfety V, Lee S, Levinson D, Medina Mora ME, Moskalewicz J, Nakamura Y, Navarro-Mateu F, Oakley Browne Mark A, Piazza M, Posada-Villa J, Slade T, ten Have M, Torres Y, Vilagut G, Xavier M, Zarkov Z, Shahly V, Wilcox MA: Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. *Epidemiol Psychiatr Sci* 2015;24:210–226.
- 11 Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH: Difference in treatment outcome in outpatients with anxious versus non-anxious depression: A STAR*D report. *Am J Psychiatry* 2008;165:342–351.
- 12 Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group: Methods of systematic reviews and meta-analysis: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62:1006–1012.
- 13 Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. *Psychother Psychosom* 2015;84:63–71.
- 14 Cochran WG: The combination of estimates from different experiments. *Biometrics* 1954;10:101–129.
- 15 Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–1558.
- 16 Begg C: Publication bias; in Cooper H (ed): *The Handbook of Research Synthesis*. New York, Russell Sage Foundation, 1994, pp 399–409.
- 17 Egger M, Davey Smith G, Schneider M, Mindorff C: Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–634.
- 18 Fabre LF, McLendon DM, Borgen LA: A comparison of trebenzomine with chlorthalidone and placebo in the treatment of anxious-depressed outpatients. *Curr Ther Res* 1979;25:311–319.
- 19 Smith WT, Glaudin V: Double-blind efficacy and safety study comparing adinazolam mesylate and placebo in depressed inpatients. *Acta Psychiatr Scand* 1986;74:238–245.
- 20 Cohn JB, Pyke RE, Wilcox CS: Adinazolam mesylate and placebo in depressed outpatients: a 6-week, double-blind comparison. *J Clin Psychiatry* 1988;49:142–147.
- 21 Rickels K, Gordon PE, Jenkins BW, Perloff M, Sachs T, Stepansky W: Drug treatment in depressive illness: amitriptyline and chlorthalidone in two neurotic populations. *Dis Nerv Syst* 1970;31:30–42.
- 22 Goldstein BJ, Brauser B, Steinbook RM, Jacobson AF: Psychotropic drug treatment of mixed anxiety and depression in nonpsychiatric office patients: expected and unexpected findings – comparing doxepin, chlorthalidone and placebo. *South Med J* 1973;66:892–897.

- 23 Shammas E: Controlled comparison of bromazepam, amitriptyline, and placebo in anxiety-depressive neurosis. *Dis Nerv Syst* 1977; 38:201–207.
- 24 Imlah NW: An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression. *Br J Psychiatry* 1985;146: 515–519.
- 25 Rickels K, Cohen D, Csanalosi I, Harris H, Koepke H, Werblowsky J: Alprazolam and imipramine in depressed outpatients: a controlled study. *Curr Ther Res* 1982;32:157–164.
- 26 Rickels K, Feighner JP, Smith WT: Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. *Arch Gen Psychiatry* 1985;42:134–141.
- 27 Lipman RS, Covi L, Rickels K, McNair DM, Downing R, Kahn RJ, Lasseter VK, Faden V: Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients. *Arch Gen Psychiatry* 1986;43:68–77.
- 28 Mendels J, Schless AP: Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. *J Clin Psychiatry* 1986;47:357–361.
- 29 Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T, Lorkowski G: Treatment of depressive outpatients with lorazepam, alprazolam, amitriptyline and placebo. *Psychopharmacology* 1995;120:109–115.
- 30 Feighner JP, Aden GC, Fabre LF, Rickels K, Smith WT: Comparison of alprazolam, imipramine, and placebo in the treatment of depression. *JAMA* 1983;249:3057–3064.
- 31 Rickels K, London J, Fox I, Hassman H, Csanalosi I, Weise C: Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. *Pharmacopsychiatry* 1991;24:127–131.
- 32 Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD: Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. *Arch Gen Psychiatry* 1987;44: 862–866.
- 33 Hicks F, Robins E, Murphy GE: Comparison of adinazolam, amitriptyline, and placebo in the treatment of melancholic depression. *Psychiatry Res* 1988;23:221–227.
- 34 Rickels K, Perloff M, Stepansky W, Dion HS, Case WG, Sapra RK: Doxepin and diazepam in general practice and hospital clinic neurotic patients: a collaborative controlled study. *Psychopharmacologia* 1969;15:265–279.
- 35 Rickels K, Chung HR, Feldman HS, Gordon PE, Kelly EA, Weise CC: Amitriptyline, diazepam, and phenobarbital sodium in depressed outpatients. *J Nerv Ment Dis* 1973; 157:442–451.
- 36 Kleber RJ: A double-blind comparative study of desipramine hydrochloride and diazepam in the control of mixed anxiety/depression symptomatology. *J Clin Psychiatry* 1979;40: 165–170.
- 37 Cropper M, Garner A, McEwan GD, Munt DF, Rushbrook LA, Stevens V, Baker AC: A double-blind comparative study of alprazolam and dothiepin hydrochloride in the treatment of anxiety associated with depression. *Pharmatherapeutica* 1987;5:76–82.
- 38 Singh AN, Nair NP, Suranyi-Cadotte B, Schwartz G, Lizondo E: A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depression. *Can J Psychiatry* 1988;33:218–222.
- 39 Banerji JR, Brantingham P, McEwan GD, Mason J, Munt DF, Renton RL, Scott AP, Strakova JM, Stevens V: A comparison of alprazolam with amitriptyline in the treatment of patients with neurotic or reactive depression. A report of a randomised, double blind study by a General Practitioner Working Party. *Ir J Med Sci* 1989;158:110–113.
- 40 Lemoine P, Boulenger J, Caillard V, Tanne N, Bonnet D: Compared efficacy of prazepam and clomipramine in major depression with anxiety: a multicenter controlled study. *Pharmacopsychiatry* 1991;24:175–179.
- 41 Yamamoto J, Kline FM, Burgoyne RW: Double-blind drug study in depressed outpatients. *Rocky Mt Med J* 1972;69:71–74.
- 42 Anseau M, Ansoms C, Beckers G, Bogaerts M, Botte L, De Buck R, Diricq S, Dumortier A, Jansegers E, Owleczka J, et al: Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. *J Affect Disord* 1984;7:287–296.
- 43 Goldberg SC, Ettigi P, Schulz PM, Hamer RM, Hayes PE, Friedel RO: Alprazolam versus imipramine in depressed out-patients with neurovegetative signs. *J Affect Disord* 1986; 11:139–145.
- 44 Eriksson B, Nagy A, Starmark JE, Thelander U: Alprazolam compared to amitriptyline in the treatment of major depression. *Acta Psychiatr Scand* 1987;75:656–663.
- 45 Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA: A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients. *Can J Psychiatry* 1988; 33:590–594.
- 46 Murthy RS, Chatterjee S, Sriram TG, Shah LP, Parikh R, Elavia S, Munjal GC, Nehru R, Ramachandran V, Nirmala G, Raghavan KS, Kumar V: A double-blind evaluation of alprazolam and imipramine in the treatment of major depression. *Indian J Psychiatry* 1991; 33:104–107.
- 47 Lapierre YD, Browne M, Oyewumi K, Sarantidis D: Alprazolam and amitriptyline in the treatment of moderate depression. *Int Clin Psychopharmacol* 1994;9:41–46.
- 48 Lenox RH, Shipley JE, Peyser JM, Williams JM, Weaver LA: Double-blind comparison of alprazolam versus imipramine in the inpatient treatment of major depressive illness. *Psychopharmacol Bull* 1984;20:79–82.
- 49 Remick RA, Fleming JA, Buchanan RA, Keller FD, Hamilton P, Loomer F, Miles JE: A comparison of the safety and efficacy of alprazolam and desipramine in moderately severe depression. *Can J Psychiatry* 1985;30:597–601.
- 50 Rush AJ, Erman MK, Schlessner MA, Roffwarg HP, Vasavada N, Khatami M, Fairchild C, Giles DE: Alprazolam vs amitriptyline in depressions with reduced REM latencies. *Arch Gen Psychiatry* 1985;42:1154.
- 51 Overall JE, Biggs J, Jacobs M, Holden K: Comparison of alprazolam and imipramine for treatment of outpatient depression. *J Clin Psychiatry* 1987;48:15–19.
- 52 Hubain PP, Castro P, Mesters P, De Maertelaer V, Mendlewicz J: Alprazolam and amitriptyline in the treatment of major depressive disorder: a double-blind clinical and sleep EEG study. *J Affect Disord* 1990;18:67–73.
- 53 Anseau M, Devoitille JM, Papart P, Vanbrabant E, Mantanus H, Timsit-Berthier M: Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variation. *J Clin Psychopharmacol* 1991;11:160–165.
- 54 Amsterdam J, Kaplan M, Potter L, Bloom L, Rickels K: Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder. *Psychopharmacology* 1986;88:484–488.
- 55 Laws D, Ashford JJ, Anstee JA: A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. *Acta Psychiatr Scand* 1990;81:185–189.
- 56 Jane-wit D, Horwitz RI, Concato J: Variation in results from randomized, controlled trials: stochastic or systematic? *J Clin Epidemiol* 2010;63:56–63.
- 57 Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 2008;358:252–260.
- 58 Fava GA: The hidden costs of financial conflicts of interest in medicine. *Psychother Psychosom* 2016;85:65–70.
- 59 Rickels K, Hesbacher P, Downing RW: Differential drug effects in neurotic depression. *Dis Nerv Syst* 1970;31:468–475.
- 60 Fava GA, Tomba E: Treatment of comorbid anxiety disorders and depression; in Emmeekamp P, Ehling T (eds): *The Wiley Handbook of Anxiety Disorders*. Chichester, John Wiley & Sons, 2014, pp 1165–1182.
- 61 Downing RW: Mixed anxiety-depression. Fact or myth? *Arch Gen Psychiatry* 1974;30: 312–317.
- 62 Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity. *JAMA* 2010;303:47.
- 63 Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M: Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. *Br J Psychiatry* 2011;198(suppl 1):11–16.

- 64 Offidani E, Guidi J, Tomba E, Fava GA: Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. *Psychother Psychosom* 2013;82:355–362.
- 65 Starcevic V: The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. *Expert Rev Neurother* 2014;14:1275–1286.
- 66 Reinhold JA, Rickels K: Pharmacological treatment for generalized anxiety disorder in adults: an update. *Expert Opin Pharmacother* 2015;16:1669–1681.
- 67 Fava GA, Balon R, Rickels K: Benzodiazepines in anxiety disorders. *JAMA Psychiatry* 2015;72:733.
- 68 Salzman C, Shader RI: Not again: benzodiazepines once more under attack. *J Clin Psychopharmacol* 2015;35:493–495.
- 69 Cloos J-M, Bocquet V, Rolland-Portal I, Koch P, Chouinard G: Hypnotics and triazolobenzodiazepines. Best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. *Psychother Psychosom* 2015;84:273–283.
- 70 American Psychiatric Association: Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Washington, APA, 1990.
- 71 Nielsen M, Hansen EH, Gøtzsche PC: What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. *Addiction* 2012;107:900–908.
- 72 Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. *Psychother Psychosom* 2015;84:72–81.
- 73 Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. *Psychother Psychosom* 2016;85:270–288.
- 74 Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD, Swanson GM, Thomson JA Jr, Mulsant BH, Andrews PW: The mortality and myocardial effects of antidepressants are moderated by preexisting cardiovascular disease: a meta-analysis. *Psychother Psychosom* 2017;86:268–282.
- 75 Fava GA, Tomba E, Bech P: Clinical pharmacopsychology: conceptual foundations and emerging tasks. *Psychother Psychosom* 2017;86:134–140.
- 76 Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson Alsaac A, Srivastava S, Nutt DJ, Davies SJC: Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J Psychiatry* 2009;184:483–490.
- 77 Fava GA, Guidi J, Rafanelli C, Rickels K: The clinical inadequacy of the placebo model and the development of an alternative conceptual framework. *Psychother Psychosom* 2017;86:332–340.